MA34054B1 - Bromhydrate d'agomelatine hydrate et sa preparation - Google Patents

Bromhydrate d'agomelatine hydrate et sa preparation

Info

Publication number
MA34054B1
MA34054B1 MA35191A MA35191A MA34054B1 MA 34054 B1 MA34054 B1 MA 34054B1 MA 35191 A MA35191 A MA 35191A MA 35191 A MA35191 A MA 35191A MA 34054 B1 MA34054 B1 MA 34054B1
Authority
MA
Morocco
Prior art keywords
preparation
bromhydrate
agomelatin
hydrate
agomelatine
Prior art date
Application number
MA35191A
Other languages
Arabic (ar)
English (en)
Inventor
Hanbin Shan
Zhedong Yuan
Xueyan Zhu
Peng Zhang
Hongjuan Pan
Xiong Yu
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44599557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34054(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of MA34054B1 publication Critical patent/MA34054B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un bromhydrate d'agomélatine hydraté de formule (i), dans laquelle x représente br, sur son procédé de préparation et son utilisation ainsi que sur une composition pharmaceutique le contenant. La solubilité du bromhydrate d'agomélatine hydraté obtenu par le présent procédé est considérablement supérieure à celle de l'agomélatine. Par conséquent, il est plus approprié pour la fabrication de formulations pharmaceutiques. En outre, le produit a une stabilité et une pureté supérieures. Le présent produit de haute pureté peut être obtenu par un procédé simple, plutôt qu'un procédé comprenant des étapes compliquées.
MA35191A 2010-03-17 2011-03-17 Bromhydrate d'agomelatine hydrate et sa preparation MA34054B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010101262639A CN102190595A (zh) 2010-03-17 2010-03-17 阿戈美拉汀溴化氢水合物及其制备方法
PCT/CN2011/071912 WO2011113363A1 (fr) 2010-03-17 2011-03-17 Bromhydrate d'agomélatine hydraté et sa préparation

Publications (1)

Publication Number Publication Date
MA34054B1 true MA34054B1 (fr) 2013-03-05

Family

ID=44599557

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35191A MA34054B1 (fr) 2010-03-17 2011-03-17 Bromhydrate d'agomelatine hydrate et sa preparation

Country Status (39)

Country Link
US (1) US8729132B2 (fr)
EP (1) EP2547650B1 (fr)
JP (1) JP5634533B2 (fr)
KR (1) KR101406736B1 (fr)
CN (2) CN102190595A (fr)
AP (1) AP3199A (fr)
AU (1) AU2011229619B2 (fr)
BR (1) BR112012023173B1 (fr)
CA (1) CA2792430C (fr)
CL (1) CL2012002541A1 (fr)
CR (1) CR20120461A (fr)
CU (1) CU20120136A7 (fr)
CY (1) CY1117134T1 (fr)
DK (1) DK2547650T3 (fr)
EA (1) EA022066B1 (fr)
EC (1) ECSP12012156A (fr)
ES (1) ES2572427T3 (fr)
GE (1) GEP20156232B (fr)
GT (1) GT201200260A (fr)
HN (1) HN2012001923A (fr)
HR (1) HRP20151343T1 (fr)
HU (1) HUE026673T2 (fr)
IL (1) IL221783A (fr)
MA (1) MA34054B1 (fr)
ME (1) ME02309B (fr)
MX (1) MX2012010594A (fr)
MY (1) MY160337A (fr)
NI (1) NI201200141A (fr)
NZ (1) NZ602451A (fr)
PE (1) PE20130014A1 (fr)
PH (1) PH12012501756A1 (fr)
PL (1) PL2547650T3 (fr)
PT (1) PT2547650E (fr)
RS (1) RS54449B1 (fr)
SG (1) SG183869A1 (fr)
SI (1) SI2547650T1 (fr)
TN (1) TN2012000436A1 (fr)
UA (1) UA105424C2 (fr)
WO (1) WO2011113363A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07115739B2 (ja) 1986-03-19 1995-12-13 株式会社石田衡器製作所 多方向仕分け装置
JPH07115742B2 (ja) 1986-03-19 1995-12-13 株式会社石田衡器製作所 多方向仕分け装置
JPH07115741B2 (ja) 1986-03-19 1995-12-13 株式会社石田衡器製作所 多方向仕分け装置
JPH07115740B2 (ja) 1986-03-19 1995-12-13 株式会社石田衡器製作所 多方向仕分け装置
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
CN102718675B (zh) * 2012-06-07 2015-03-25 上海右手医药科技开发有限公司 阿戈美拉汀甲磺酸复合物及其制备方法
EP2851363B1 (fr) * 2012-05-14 2018-01-03 Shanghai Righthand Pharmtech. Co., Ltd. Composite à base de radical acide d'agomélatine et procédé de préparation et application associés

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ES2204358T1 (es) * 2000-10-30 2004-05-01 Teva Pharmaceutical Industries Ltd. Nuevas formas de cristal y de disolvente de hidrocloruro de ondasetron y procedimientos para su preparacion.
FR2890562B1 (fr) * 2005-09-09 2012-10-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用

Also Published As

Publication number Publication date
KR20120128713A (ko) 2012-11-27
KR101406736B1 (ko) 2014-06-12
ES2572427T3 (es) 2016-05-31
ME02309B (me) 2016-06-20
AU2011229619A1 (en) 2012-09-27
HUE026673T2 (en) 2016-07-28
CN102892749B (zh) 2014-11-05
CY1117134T1 (el) 2017-04-05
ECSP12012156A (es) 2012-12-28
AP2012006493A0 (en) 2012-10-31
PL2547650T3 (pl) 2016-06-30
PH12012501756A1 (en) 2012-11-12
EP2547650A4 (fr) 2013-09-18
NZ602451A (en) 2014-10-31
HK1177732A1 (en) 2013-08-30
EP2547650B1 (fr) 2015-11-04
NI201200141A (es) 2012-11-09
AU2011229619B2 (en) 2014-05-22
BR112012023173B1 (pt) 2021-08-24
SG183869A1 (en) 2012-10-30
MY160337A (en) 2017-02-28
US8729132B2 (en) 2014-05-20
GT201200260A (es) 2013-11-18
TN2012000436A1 (en) 2014-01-30
CN102892749A (zh) 2013-01-23
HN2012001923A (es) 2015-09-14
RS54449B1 (sr) 2016-06-30
CR20120461A (es) 2012-11-29
EA201201293A1 (ru) 2013-04-30
IL221783A (en) 2017-11-30
PT2547650E (pt) 2015-11-30
BR112012023173A2 (pt) 2016-05-17
HRP20151343T1 (hr) 2016-01-01
DK2547650T3 (en) 2016-02-15
CA2792430A1 (fr) 2011-09-22
JP2013522242A (ja) 2013-06-13
UA105424C2 (uk) 2014-05-12
AP3199A (en) 2015-03-31
GEP20156232B (en) 2015-01-26
SI2547650T1 (sl) 2016-02-29
WO2011113363A1 (fr) 2011-09-22
US20130012592A1 (en) 2013-01-10
JP5634533B2 (ja) 2014-12-03
MX2012010594A (es) 2012-10-03
EP2547650A1 (fr) 2013-01-23
CL2012002541A1 (es) 2013-01-11
PE20130014A1 (es) 2013-01-26
CU20120136A7 (es) 2012-12-17
EA022066B1 (ru) 2015-10-30
CA2792430C (fr) 2015-12-08
CN102190595A (zh) 2011-09-21

Similar Documents

Publication Publication Date Title
MA33224B1 (fr) Derives de proline comme inhibiteurs de la cathepsine
MY160460A (en) Agomelatine hydrochloride hydrate and preparation thereof
JOP20190072A1 (ar) مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
UA105425C2 (ru) Кристаллическая форма агомелатина гидрохлорида гидрата и способ ее получения
MA33356B1 (fr) Compose anticancereux et composition pharmaceutique le contenant
MA27518A1 (fr) Nouveau procede de synthese et nouvelle forme cristalline de l'agomelatine ainsi que les compositions pharmaceutiques qui la contiennent
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA30694B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
EA201170289A1 (ru) Фармацевтические композиции и способы их получения при низкой концентрации примесей
EA201990688A1 (ru) Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение
JP2014058449A (ja) アミド誘導体及び安定性指標としてのその使用
MA34313B1 (fr) Formulation pharmaceutique sous la forme de comprimés bicouches comprenant un inhibiteur de hmg-coa réductase et d'irbésartan
EA201201293A1 (ru) Гидрат гидробромида агомелатина и его получение
MA35158B1 (fr) Formulations topiques de type suspension comprenant un depsipeptide cyclique
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MX339685B (es) Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas.
MA34958B1 (fr) Nouvelle forme cristalline vii d'agomelatine ,son procedes de preparation et utilisation et composition pharmaceutique la contenant
MA37524A1 (fr) Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee
MX2009008068A (es) Compuesto macrolido en forma solida, proceso para su preparacion y composicion farmaceutica que lo contiene.
CN1293864C (zh) 含有用磺异苯酮稳定的酮洛芬的局部用制剂
JP6028606B2 (ja) アミン化合物の製造方法
CN105218428A (zh) 一种高手性纯度的阿普斯特的制备方法
MA37941B1 (fr) Dérivés d'aryléthynyle
FR3095437B1 (fr) Procédé d’obtention de bromure de tétraéthylammonium et de tétrafluoroborate de tétraéthylammonium, produits et utilisations correspondants
MA37879A1 (fr) Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant